Past Prediabetes Linked to Lasting CKM Risk, Study Finds

Originally surfaced June 19, 2026, drawing on a Frontiers in Endocrinology article published June 16, 2026.

A new prospective cohort study argues for taking a person's glucose history seriously, not just the latest fasting glucose value.

The study followed 43,073 adults in the Kailuan cohort in China who had examinations in 2006 and 2010 and were free of cardiovascular disease, type 2 diabetes, and chronic kidney disease at baseline. Researchers grouped participants by impaired fasting glucose trajectory: sustained normal fasting glucose, progression to impaired fasting glucose, recovery from impaired fasting glucose, or persistent impaired fasting glucose. Follow-up continued through 2021.

The primary outcome was cardio-kidney-metabolic multimorbidity, defined as at least two of cardiovascular disease, type 2 diabetes, or chronic kidney disease. Over a median 11.0 years of follow-up, 1,795 participants developed that outcome.

Compared with people who had sustained normal fasting glucose, adjusted hazard ratios were 1.93 for IFG progression, 1.69 for IFG recovery, and 3.10 for persistent IFG. When IFG recovery was used as the reference group, sustained fasting-glucose health was associated with lower risk, while persistent IFG remained higher risk.

That is the news hook: in this cohort, glucose values that returned to normal did not erase the long-term risk signal linked to an earlier impaired fasting glucose period.

Why fasting glucose history matters

A fasting glucose test is a snapshot. It reports glucose concentration after a fasting period, often used with A1c and other context to evaluate diabetes and prediabetes risk. A normal result is useful, but it does not necessarily summarize the last decade of metabolic exposure.

This study looked at trajectory, not a single lab draw. That distinction is the value of the paper. A person who moved from impaired fasting glucose back to normal fasting glucose had lower risk than someone with persistent impaired fasting glucose, but higher risk than someone who stayed normal across both examination points.

The 2026 AHA/ACC/ADA/ASN guideline for cardiovascular-kidney-metabolic syndrome fits the same basic frame: metabolic risk, kidney disease, and cardiovascular disease are connected rather than isolated silos. The Frontiers paper is not a clinical-management guideline, but it adds population-level glucose-trajectory data to that broader CKM discussion.

The LTS testing context

LabTestSuperstore has background pages for fasting glucose testing, Hemoglobin A1c, fasting insulin, and a broader diabetes panel. Those tests answer related but different metabolic questions.

Fasting glucose is a point-in-time blood sugar measure. A1c reflects a longer average glucose window. Fasting insulin can add context about how hard the body may be working to maintain glucose levels. A comprehensive metabolic panel also includes glucose as one component among kidney, liver, electrolyte, and protein markers.

This article is not saying that everyone with a prior abnormal fasting glucose result needs the same follow-up plan. It is saying the longitudinal pattern may carry information that a single current glucose value misses.

What not to overread

The Kailuan cohort is not a perfect match for a U.S. direct-to-consumer lab-testing audience. It is a Chinese occupational cohort with its own demographic and exposure profile. The study is observational, so it can show association, not prove that an impaired fasting glucose episode directly caused later multimorbidity.

The outcome is also broad. Cardio-kidney-metabolic multimorbidity combines cardiovascular disease, type 2 diabetes, and chronic kidney disease. That makes the endpoint clinically interesting, but it also means the article should not be reduced to a simple diabetes prediction story.

The clean takeaway is narrower: in this cohort, prior impaired fasting glucose remained associated with higher long-term risk even when fasting glucose later normalized. That supports paying attention to glucose history and trend context, not just the most recent normal result.

This article is editorial commentary and is not medical advice. It has not been reviewed by a physician and should not be used to make decisions about diabetes diagnosis, kidney disease, cardiovascular risk, testing frequency, medication, or treatment.